Treatment of giant cell arteritis - current approach and new possibilities.
Vnitr Lek
; 68(5): 266-272, 2022.
Article
en En
| MEDLINE
| ID: mdl-36283815
ABSTRACT
Giant Cell Arteritis (GCA) is an autoimmune mediated systemic vasculitis affecting large arteries - the aorta and its branches. It has the highest incidence of all systemic vasculitides and manifests nearly exclusively in patients aged 50 or older. Amongst its non-specific and specific symptoms are headaches, mastication claudication or signs of rheumatic polymyalgia, a relatively common and immediate treatment requiring condition being acute vision loss due to optic ischemia. A GCA diagnosis is based on clinical and paraclinical findings and imaging techniques including PET/CT; with an important role still being played by histological verification from temporal artery biopsy. Treatment is based on immunosuppressive agents - systemic glucocorticoids, with adjunct therapy options being methotrexate and tocilizumab. Currently, there are also several clinical trials examining the efficacy of other modern biological agents in GCA.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Arteritis de Células Gigantes
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article